Luteolin as a therapeutic option for multiple sclerosis

Journal of Neuroinflammation

Volumn 6, Issue , 2009, Pages 29-

  Theoharides, Theoharis C ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; FLAVONOID; GELATINASE B; INTERLEUKIN 6; INTERLEUKIN 8; LUTEOLIN; QUERCETIN; TRYPTASE; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC ENCEPHALITIS; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG METABOLISM; ENZYME INHIBITION; HUMAN; LEUKOCYTE ACTIVATION; MAST CELL; MULTIPLE SCLEROSIS; NEUROPATHOLOGY; NONHUMAN; NOTE; T LYMPHOCYTE ACTIVATION; UNSPECIFIED SIDE EFFECT;

ANIMALS; BRAIN; HUMANS; INTERFERON-BETA; LUTEOLIN; MULTIPLE SCLEROSIS; QUERCETIN;

EID: 70449707436     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-6-29     Document Type: Note

References (37)

1. Sternberg Z, Chadha K, Lieberman A, Hojnacki D, Drake A, Zamboni P, Rocco P, Grazioli E, Weinstock-Guttman B, Munschauer F. Quercetin and interferon-beta modulate immune response(s) in peripheral blood mononuclear cells isolated from multiple sclerosis patients. J Neuroimmunol 2008, 205:142-147. 10.1016/j.jneuroim.2008.09.008, 18926575.
2. Kempuraj D, Tagen M, Iliopoulou BP, Clemons A, Vasiadi M, Boucher W, House M, Wolfberg A, Theoharides TC. Luteolin inhibits myelin basic protein-induced human mast cell activation and mast cell dependent stimulation of Jurkat T cells. Br J Pharmacol 2008, 155:1076-1084. 10.1038/bjp.2008.356, 18806808.
3. Robbie-Ryan M, Tanzola MB, Secor VH, Brown MA. Cutting edge: both activating and inhibitory Fc receptors expressed on mast cells regulate experimental allergic encephalomyelitis disease severity. J Immunol 2003, 170:1630-1634.
4. Pedotti R, De Voss JJ, Steinman L, Galli SJ. Involvement of both 'allergic' and 'autoimmune' mechanisms in EAE, MS and other autoimmune diseases. Trends Immunol 2003, 24:479-484. 10.1016/S1471-4906(03)00233-3, 12967671.
5. Pedotti R, DeVoss JJ, Youssef S, Mitchell D, Wedemeyer J, Madanat R, Garren H, Fontoura P, Tsai M, Galli SJ, Sobel RA, Steinman L. Multiple elements of the allergic arm of the immune response modulate autoimmune demyelination. Proc Natl Acad Sci USA 2003, 100:1867-1872. 10.1073/pnas.252777399, 149925, 12576552.
6. Theoharides TC. Mast cells: the immune gate to the brain. Life Sci 1990, 46:607-617. 10.1016/0024-3205(90)90129-F, 2407920.
7. Zappulla JP, Arock M, Mars LT, Liblau RS. Mast cells: new targets for multiple sclerosis therapy?. J Neuroimmunol 2002, 131:5-20. 10.1016/S0165-5728(02)00250-3, 12458032.
8. Theoharides TC, Cochrane DE. Critical role of mast cells in inflammatory diseases and the effect of acute stress. J Neuroimmunol 2004, 146:1-12. 10.1016/j.jneuroim.2003.10.041, 14698841.
9. Olsson Y. Mast cells in plaques of multiple sclerosis. Acta Neurol Scand 1974, 50:611-618.
10. Krüger PG, Bø L, Myhr KM, Karlsen AE, Taule A, Nyland HI, Mørk S. Mast cells and multiple sclerosis: a light and electron microscopic study of mast cells in multiple sclerosis emphasizing staining procedures. Acta Neurol Scand 1990, 81:31-36.
11. Dietsch GN, Hinrichs DJ. The role of mast cells in the elicitation of experimental allergic encephalomyelitis. J Immunol 1989, 142:1476-1481.
12. Johnson D, Seeldrayers PA, Weiner HL. The role of mast cells in demyelination. 1. Myelin proteins are degraded by mast cell proteases and myelin basic protein and P2 can stimulate mast cell degranulation. Brain Res 1988, 444:195-198. 10.1016/0006-8993(88)90929-8, 2451996.
13. Theoharides TC, Dimitriadou V, Letourneau RJ, Rozniecki JJ, Vliagoftis H, Boucher WS. Synergistic action of estradiol and myelin basic protein on mast cell secretion and brain demyelination: changes resembling early stages of demyelination. Neuroscience 1993, 57:861-871. 10.1016/0306-4522(93)90030-J, 7508580.
14. Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H, Langer-Gould A, Strober S, Cannella B, Allard J, Klonowski P, Austin A, Lad N, Kaminski N, Galli SJ, Oksenberg JR, Raine CS, Heller R, Steinman L. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 2002, 8:500-508. 10.1038/nm0502-500, 11984595.
15. Bomprezzi R, Ringnér M, Kim S, Bittner ML, Khan J, Chen Y, Elkahloun A, Yu A, Bielekova B, Meltzer PS, Martin R, McFarland HF, Trent JM. Gene expression profile in multiple sclerosis patients and healthy controls: identifying pathways relevant to disease. Hum Mol Genet 2003, 12:2191-2199. 10.1093/hmg/ddg221, 12915464.
16. De Jager PL, Hafler DA. Gene expression profiling in MS: what is the clinical relevance?. Lancet Neurol 2004, 3:269. 10.1016/S1474-4422(04)00731-8, 15099539.
17. Rozniecki JJ, Hauser SL, Stein M, Lincoln R, Theoharides TC. Elevated mast cell tryptase in cerebrospinal fluid of multiple sclerosis patients. Ann Neurol 1995, 37:63-66. 10.1002/ana.410370112, 7818259.
18. Malamud V, Vaaknin A, Abramsky O, Mor M, Burgess LE, Ben-Yehudah A, Lorberboum-Galski H. Tryptase activates peripheral blood mononuclear cells causing the synthesis and release of TNF-alpha, IL-6 and IL-1 beta: possible relevance to multiple sclerosis. J Neuoimmunol 2003, 138:115-122.
19. Molino M, Barnathan ES, Numerof R, Clark J, Dreyer M, Cumashi A, Hoxie JA, Schechter N, Woolkalis M, Brass LF. Interactions of mast cell tryptase with thrombin receptors and PAR-2. J Biol Chem 1997, 272:4043-4049. 10.1074/jbc.272.7.4043, 9020112.
20. Cocchiara R, Bongiovanni A, Albeggiani G, Azzolina A, Geraci D. Evidence that brain mast cells can modulate neuroinflammatory responses by tumor necrosis factor-α production. Neuroreport 1998, 9:95-98. 10.1097/00001756-199801050-00019, 9592055.
21. Probert L, Akassoglou K, Kassiotis G, Pasparakis M, Alexopoulou L, Kollias G. TNF-α transgenic and knockout models of CNS inflammation and degeneration. J Neuroimmunol 1997, 72:137-141. 10.1016/S0165-5728(96)00184-1, 9042105.
22. Kim KS, Wass CA, Cross AS, Opal SM. Modulation of blood-brain barrier permeability by tumor necrosis factor and antibody to tumor necrosis factor in the rat. Lymphokine Cytokine Res 1992, 11:293-298.
23. Kermode AG, Thompson AJ, Tofts P, MacManus DG, Kendall BE, Kingsley DP, Moseley IF, Rudge P, McDonald WI. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Brain 1990, 113:1477-1489. 10.1093/brain/113.5.1477, 2245307.
24. Esposito P, Chandler N, Kandere K, Basu S, Jacobson S, Connolly R, Tutor D, Theoharides TC. Corticotropin-releasing hormone (CRH) and brain mast cells regulate blood-brain-barrier permeability induced by acute stress. J Pharmacol Exp Ther 2002, 303:1061-1066. 10.1124/jpet.102.038497, 12438528.
25. Esposito P, Gheorghe D, Kandere K, Pang X, Connolly R, Jacobson S, Theoharides TC. Acute stress increases permeability of the blood-brain-barrier through activation of brain mast cells. Brain Res 2001, 888:117-127. 10.1016/S0006-8993(00)03026-2, 11146058.
26. Middleton E, Kandaswami C, Theoharides TC. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease and cancer. Pharmacol Rev 2000, 52:673-751.
27. Kimata M, Shichijo M, Miura T, Serizawa I, Inagaki N, Nagai H. Effects of luteolin, quercetin and baicalein on immunoglobulin E-mediated mediator release from human cultured mast cells. Clin Exp Allergy 2000, 30:501-508. 10.1046/j.1365-2222.2000.00768.x, 10718847.
28. Kempuraj D, Madhappan B, Christodoulou S, Boucher W, Cao J, Papadopoulou N, Cetrulo CL, Theoharides TC. Flavonols inhibit proinflammatory mediator release, intracellular calcium ion levels and protein kinase C theta phosphorylation in human mast cells. Br J Pharmacol 2005, 145:934-944. 10.1038/sj.bjp.0706246, 1576204, 15912140.
29. Park HH, Lee S, Son HY, Park SB, Kim MS, Choi EJ, Singh TS, Ha JH, Lee MG, Kim JE, Hyun MC, Kwon TK, Kim YH, Kim SH. Flavonoids inhibit histamine release and expression of proinflammatory cytokines in mast cells. Arch Pharm Res 2008, 31:1303-1311. 10.1007/s12272-001-2110-5, 18958421.
30. Kandere-Grzybowska K, Kempuraj D, Cao J, Cetrulo CL, Theoharides TC. Regulation of IL-1-induced selective IL-6 release from human mast cells and inhibition by quercetin. Br J Pharmacol 2006, 148:208-215. 10.1038/sj.bjp.0706695, 1617055, 16532021.
31. Jang S, Kelley KW, Johnson RW. Luteolin reduces IL-6 production in microglia by inhibiting JNK phosphorylation and activation of AP-1. Proc Natl Acad Sci USA 2008, 105:7534-7539. 10.1073/pnas.0802865105, 2396685, 18490655.
32. Sharma V, Mishra M, Ghosh S, Tewari R, Basu A, Seth P, Sen E. Modulation of interleukin-1beta mediated inflammatory response in human astrocytes by flavonoids: implications in neuroprotection. Brain Res Bull 2007, 73:55-63. 10.1016/j.brainresbull.2007.01.016, 17499637.
33. Hendriks JJ, de Vries HE, Pol SM, Berg TK, van Tol EA, Dijkstra CD. Flavonoids inhibit myelin phagocytosis by macrophages; a structure-activity relationship study. Biochem Pharmacol 2003, 65:877-885. 10.1016/S0006-2952(02)01609-X, 12628496.
34. Aktas O, Prozorovski T, Smorodchenko A, Savaskan NE, Lauster R, Kloetzel PM, Infante-Duarte C, Brocke S, Zipp F. Green tea epigallocatechin-3-gallate mediates T cellular NF-kappa B inhibition and exerts neuroprotection in autoimmune encephalomyelitis. J Immunol 2004, 173:5794-5800.
35. Muthian G, Bright JJ. Quercetin, a flavonoid phytoestrogen, ameliorates experimental allergic encephalomyelitis by blocking IL-12 signaling through JAK-STAT pathway in T lymphocyte. J Clin Immunol 2004, 24:542-552. 10.1023/B:JOCI.0000040925.55682.a5, 15359113.
36. Hendriks JJ, Alblas J, Pol SM, van Tol EA, Dijkstra CD, de Vries HE. Flavonoids influence monocytic GTPase activity and are protective in experimental allergic encephalitis. J Exp Med 2004, 200:1667-1672. 10.1084/jem.20040819, 2212002, 15611292.
37. Manach C, Donovan JL. Pharmacokinetics and metabolism of dietary flavonoids in humans. Free Radic Res 2004, 38:771-785. 10.1080/10715760410001727858, 15493450.